Abstract
The recent discovery of cancer stem cells (CSCs) has played a pivotal role in changing our view of carcinogenesis and chemotherapy. Based on this concept, CSCs are responsible for the formation and growth of neoplastic tissue and are naturally resistant to chemotherapy, explaining why traditional chemotherapies can initially shrink a tumor but fails to eradicate it in full, allowing eventual recurrence. Recently, we identified a CSC population in hepatocellular carcinoma (HCC) characterized by their CD133 phenotype. However, the molecular mechanism by which it escapes conventional therapies remains unknown. Here, we examined the sensitivity of these cells to chemotherapeutic agents (doxorubicin and fluorouracil) and the possible mechanistic pathway by which resistance may be regulated. Purified CD133+ HCC cells isolated from human HCC cell line and xenograft mouse models survived chemotherapy in increased proportions relative to most tumor cells which lack the CD133 phenotype; the underlying mechanism of which required the preferential expression of survival proteins involved in the Akt/PKB and Bcl-2 pathway. Treatment of CD133+ HCC cells with an AKT1 inhibitor, specific to the Akt/PKB pathway, significantly reduced the expression of the survival proteins that was normally expressed endogenously. In addition, treatment of unsorted HCC cells with both anticancer drugs in vitro significantly enriched the CD133+ subpopulation. In conclusion, our results show that CD133+ HCC cells contribute to chemoresistance through preferential activation of Akt/PKB and Bcl-2 cell survival response. Targeting of this specific survival signaling pathway in CD133+ HCC CSCs may provide a novel therapeutic model for the disease.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Adams JM, Cory S . (1998). The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322–1326.
Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF . (2003). Prospective identification of tumorigenic breast cancer cells. 100: 3983–3988.
Bonnet D, Dick JE . (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 3: 730–737.
Collins AT, Berry PA, Hyde C, Stower MJ, Maitland NJ . (2005). Prospective identification of tumorigenic prostate cancer stem cells. Cancer Res 65: 10946–10951.
Datta SR, Dudek H, Tao X, Masters S, Fu H, Gotoh Y et al. (1997). Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell 91: 231–241.
Dean M, Fojo T, Bates S . (2005). Tumor stem cells and drug resistance. Nat Rev Cancer 5: 275–284.
Fabregat I, Roncero C, Fernandez M . (2007). Survival and apoptosis: a dysregulated balance in liver cancer. Liver Int 27: 155–162.
Fesik SW . (2005). Promoting apoptosis as a strategy for cancer drug discovery. Nat Rev Cancer 5: 876–885.
Hanahan D, Weinberg RA . (2000). The hallmarks of cancer. Cell 100: 57–70.
Haraguchi N, Utsunomiya T, Inoue H, Tanaka F, Mimori K, Barnard GF et al. (2006). Characterization of a side population of cancer cells from human gastrointestinal system. Stem Cells 24: 506–513.
Hemmati HD, Nakano I, Lazareff JA, Masterman-Smith M, Geschwind DH, Bronner-Fraser M et al. (2003). Cancerous stem cells can arise from pediatric brain tumors. 100: 15178–15183.
Lapidot T, Sirard C, Vormoor J, Murdoch B, Hoang T, Caceres-Cortes J et al. (1994). A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 367: 645–648.
Li CW, Heidt DG, Dalerba P, Burant CF, Zhang LJ, Adsay V et al. (2007). Identification of pancreatic cancer stem cells. Cancer Res 67: 1030–1037.
Ma S, Chan KW, Hu L, Lee TK, Wo JY, Ng IO et al. (2007). Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology 132: 2542–2556.
Nakabayashi H, Taketa K, Miyano K, Yamane T, Sato J . (1982). Growth of human hepatoma cell lines with differentiated functions in chemically defined medium. Cancer Res 42: 3858–3863.
Nicholson KM, Anderson NG . (2002). The protein kinase B/Akt signaling pathway in human malignancy. Cell Signal 14: 381–395.
O’Brien CA, Pollett A, Gallinger S, Dick JE . (2007). A human colon cancer cell capable of initiating tumor growth in immunodeficient mice. Nature 445: 106–110.
Pardal R, Clarke MF, Morrison SJ . (2003). Applying the principles of stem-cell biology to cancer. Nat Rev Cancer 3: 895–902.
Patrawala L, Calhoun T, Schneider-Broussard R, Li H, Bhatia B, Tang S et al. (2006). Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells. Oncogene 25: 1696–1708.
Ponti D, Costa A, Zaffaroni N, Pratesi G, Petrangolini G, Coradini D et al. (2005). Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. Cancer Res 65: 5506–5511.
Reya T, Morrison SJ, Clarke MF, Weissman IL . (2001). Stem cells, cancer and cancer stem cells. Nature 414: 105–111.
Ricci-Vitiani L, Lombardi DG, Pilozzi E, Biffoni M, Todaro M, Peschle C et al. (2007). Identification and expansion of human colon-cancer-initiating cells. Nature 445: 111–115.
Sebolt-Leopold JS, Herrera R . (2004). Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat Rev Cancer 4: 937–947.
Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J et al. (2003). Identification of a cancer stem cell in human brain tumors. Cancer Res 63: 5821–5828.
Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T et al. (2004). Identification of human brain tumor initiating cells. Nature 432: 396–401.
Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H . (2006). Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun 351: 820–824.
Thorgeirsson SS, Grisham JW . (2002). Molecular pathogenesis of human hepatocellular carcinoma. Nat Genet 31: 339–346.
Vivanco I, Sawyers CL . (2002). The phosphatidylinositol 3-Kinase Akt pathway in human cancer. Nat Rev Cancer 2: 489–501.
Yin S, Li J, Hu C, Chen X, Yao M, Yan M et al. (2007). CD133 positive hepatocellular carcinoma cells possess high capacity for tumorigenicity. Int J Cancer 120: 1436–1442.
Acknowledgements
We would like to thank Fai Ng for his help with the cell sorting facility. This study is supported by the Research Fund for the Control of Infectious Diseases (02040162) and the Research Grant Council (HKU 7393/04M).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Ma, S., Lee, T., Zheng, BJ. et al. CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway. Oncogene 27, 1749–1758 (2008). https://doi.org/10.1038/sj.onc.1210811
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1210811
Keywords
This article is cited by
-
Engineered extracellular vesicles mediated CRISPR-induced deficiency of IQGAP1/FOXM1 reverses sorafenib resistance in HCC by suppressing cancer stem cells
Journal of Nanobiotechnology (2023)
-
SPINK1-induced tumor plasticity provides a therapeutic window for chemotherapy in hepatocellular carcinoma
Nature Communications (2023)
-
Portal vein tumor thrombosis in hepatocellular carcinoma: molecular mechanism and therapy
Clinical & Experimental Metastasis (2023)
-
The critical role of circular RNAs in drug resistance in gastrointestinal cancers
Medical Oncology (2023)
-
The emerging role of the gut microbiome in cancer cell plasticity and therapeutic resistance
Cancer and Metastasis Reviews (2023)